Skip to content

Using the Ending Self-Stigma Intervention to Reduce Internalized Stigma Among People Living With HIV Who Use Substances

IRIS: Intervention to Reduce Internalized Stigma (IRIS) Among People Living With HIV Who Use Substances

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05704764
Acronym
IRIS
Enrollment
70
Registered
2023-01-30
Start date
2023-02-17
Completion date
2026-06-30
Last updated
2025-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV, Stigma, Social, Substance Use

Keywords

cognitive behavioral therapy, social cognitive theory, stigma

Brief summary

The goal of this clinical trial is to test an intervention to reduce stigma among people living with HIV who use opioids and cocaine. The main question it aims to answer is: \- Does reducing internalized stigma about HIV and/or drug use lead to improved HIV care outcomes? After a year spent adapting an existing intervention to be applied specifically among people living with HIV who use substances, 70 participants will be randomized to receive either treatment-as-usual or the newly adapted intervention. The intervention itself will consist of five one-on-one sessions with a trained interventionist to discuss and work through the stigmas people commonly associate with HIV and/or substance use.

Detailed description

Different types of stigma (e.g., anticipated, enacted, internalized) associated with illicit substance use (SU) and HIV positive status impede HIV treatment outcomes (incl. HIV healthcare retention, antiretroviral therapy \[ART\] adherence and viral load suppression). The premise of this study is that individuals can learn to diminish the personal effects of public stigma, thereby reducing internalized stigma and improving expected health outcomes. To this end, this study adapted an existing evidence-based stigma reduction intervention, Ending Self-Stigma (ESS), which has shown efficacy in reducing internalized and anticipated stigma in populations experiencing mental health challenges, to be applied specifically among people living with HIV and using drugs and/or alcohol (or are currently in treatment for substance use). The new one-on-one intervention is IRIS, and it uses cognitive behavioral therapy strategies and social cognitive theory constructs to facilitate reductions in internalized stigma. In the first phase, an iterative process beginning with formative interviews with service delivery key informants and people living with HIV/AIDS (PLWH) who use substances generated an initial version of IRIS. Intervention content was adapted based on participant feedback and intervention delivery was adapted for a virtual format. In the second phase, a small pilot of the newly created IRIS intervention was carried out with persons living with HIV and using substances. Feedback from participants and intervention staff were used to refine the IRIS intervention. In the third phase, a clinical trial testing the newly adapted IRIS intervention will be carried out with 70 participants (Group 1: Minimally Enhanced Treatment-as-Usual; Group 2: IRIS; 1:1 randomization) to determine feasibility and acceptability of the intervention in addition to collecting data on intervening variables (incl. internalized and anticipated stigma, depressive symptoms, anxiety, etc.).

Interventions

BEHAVIORALEnding Self Stigma for Persons living with HIV and Use Substances

One-on-one intervention based on principles of cognitive behavioral therapy and social cognitive theory designed to reduce internalized stigma related to HIV and/or drug use.

Sponsors

University of Maryland
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Johns Hopkins University
CollaboratorOTHER
Friends Research Institute, Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Two group randomized (1:1) design contrasting minimally enhanced treatment-as-usual (ME-TAU) with the IRIS intervention.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18+ years of age * English speaking * Living with HIV * Self-report recent drug and/or alcohol use OR currently enrolled in substance use treatment * Willing and able to provide full informed consent * Responds affirmatively to having ever experienced one or more of the following types of stigma related to HIV status or SU: (1) enacted, (2) anticipated, and/or internalized.

Exclusion criteria

* Does not meet all inclusion criteria.

Design outcomes

Primary

MeasureTime frameDescription
HIV-Related Internalized Stigma30 DaysChange in Berger HIV Stigma scale scores (1 to 4, with higher scores meaning more internalized stigma)
Substance Use-Related Internalized Stigma30 daysChanges in Substance Use Stigma Mechanism scores (1 to 5, with higher scores meaning more internalized stigma)

Secondary

MeasureTime frameDescription
ART Adherence30 daysChange in self-reported ART adherence (5-point scale, with larger numbers meaning better ART adherence)
Mental Health Symptoms7 daysChanges in CES-D (1 to 4, with larger numbers meaning more depression symptoms) and Spielberger Anxiety (1 to 4, with larger numbers meaning more anxiety) scale scores.
Intervention Satisfaction30 daysParticipant intervention satisfaction scores (1 to 5, with larger numbers meaning greater intervention satisfaction)
Substance Use30 daysSelf-reported days of substance use

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026